Cargando…

A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study

BACKGROUND: To prevent debilitating and irreversible joint damage, rheumatoid arthritis (RA) is often treated with tumor necrosis factor inhibitor (TNFi), but many patients do not respond to this costly therapy. Few predictors for response are known, and it has been proposed that genetic factors whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xia, Askling, Johan, Saevarsdottir, Saedis, Padyukov, Leonid, Alfredsson, Lars, Viatte, Sebastien, Frisell, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135751/
https://www.ncbi.nlm.nih.gov/pubmed/27912794
http://dx.doi.org/10.1186/s13075-016-1174-z
_version_ 1782471600342302720
author Jiang, Xia
Askling, Johan
Saevarsdottir, Saedis
Padyukov, Leonid
Alfredsson, Lars
Viatte, Sebastien
Frisell, Thomas
author_facet Jiang, Xia
Askling, Johan
Saevarsdottir, Saedis
Padyukov, Leonid
Alfredsson, Lars
Viatte, Sebastien
Frisell, Thomas
author_sort Jiang, Xia
collection PubMed
description BACKGROUND: To prevent debilitating and irreversible joint damage, rheumatoid arthritis (RA) is often treated with tumor necrosis factor inhibitor (TNFi), but many patients do not respond to this costly therapy. Few predictors for response are known, and it has been proposed that genetic factors which influence the development of RA may also influence disease severity and response to therapy. Several previous studies have attempted to confirm this but results remain inconclusive. We expand on previous studies by including more RA risk alleles, and maximize power by combining them into a genetic risk score. METHOD: We linked genotyped RA patients from the Epidemiological Investigation of Rheumatoid Arthritis study to the Swedish Rheumatology Quality Register, identifying patients who started a TNFi as their first biological disease-modifying anti-rheumatic drug, with a return visit within 2–8 months after treatment start (N = 867). We calculated risk scores from 76 established RA risk SNPs, and four HLA-DRB1 amino acid positions, and tested whether risk scores or individual genetic risk factors could predict the European League Against Rheumatism (EULAR) response. RESULTS: We found no association between any of the risk scores or HLA-DRB1 haplotypes and EULAR response, neither overall nor stratified by anti-citrullinated protein/peptide antibody (ACPA) status. When evaluating each of the 76 SNPs, we found that the number of SNPs presenting significant associations was not higher than expected by chance (5/76 SNPs had p < 0.05 in ACPA-positive RA, 4/76 in ACPA-negative RA). CONCLUSION: Overall, known RA risk SNPs do not predict response to TNFi, either individually or when combined into a risk score. This does not support the hypothesis that genes influencing RA onset would also influence its prognosis and treatment response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1174-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5135751
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51357512016-12-15 A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study Jiang, Xia Askling, Johan Saevarsdottir, Saedis Padyukov, Leonid Alfredsson, Lars Viatte, Sebastien Frisell, Thomas Arthritis Res Ther Research Article BACKGROUND: To prevent debilitating and irreversible joint damage, rheumatoid arthritis (RA) is often treated with tumor necrosis factor inhibitor (TNFi), but many patients do not respond to this costly therapy. Few predictors for response are known, and it has been proposed that genetic factors which influence the development of RA may also influence disease severity and response to therapy. Several previous studies have attempted to confirm this but results remain inconclusive. We expand on previous studies by including more RA risk alleles, and maximize power by combining them into a genetic risk score. METHOD: We linked genotyped RA patients from the Epidemiological Investigation of Rheumatoid Arthritis study to the Swedish Rheumatology Quality Register, identifying patients who started a TNFi as their first biological disease-modifying anti-rheumatic drug, with a return visit within 2–8 months after treatment start (N = 867). We calculated risk scores from 76 established RA risk SNPs, and four HLA-DRB1 amino acid positions, and tested whether risk scores or individual genetic risk factors could predict the European League Against Rheumatism (EULAR) response. RESULTS: We found no association between any of the risk scores or HLA-DRB1 haplotypes and EULAR response, neither overall nor stratified by anti-citrullinated protein/peptide antibody (ACPA) status. When evaluating each of the 76 SNPs, we found that the number of SNPs presenting significant associations was not higher than expected by chance (5/76 SNPs had p < 0.05 in ACPA-positive RA, 4/76 in ACPA-negative RA). CONCLUSION: Overall, known RA risk SNPs do not predict response to TNFi, either individually or when combined into a risk score. This does not support the hypothesis that genes influencing RA onset would also influence its prognosis and treatment response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1174-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-12-03 2016 /pmc/articles/PMC5135751/ /pubmed/27912794 http://dx.doi.org/10.1186/s13075-016-1174-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jiang, Xia
Askling, Johan
Saevarsdottir, Saedis
Padyukov, Leonid
Alfredsson, Lars
Viatte, Sebastien
Frisell, Thomas
A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
title A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
title_full A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
title_fullStr A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
title_full_unstemmed A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
title_short A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
title_sort genetic risk score composed of rheumatoid arthritis risk alleles, hla-drb1 haplotypes, and response to tnfi therapy – results from a swedish cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135751/
https://www.ncbi.nlm.nih.gov/pubmed/27912794
http://dx.doi.org/10.1186/s13075-016-1174-z
work_keys_str_mv AT jiangxia ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT asklingjohan ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT saevarsdottirsaedis ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT padyukovleonid ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT alfredssonlars ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT viattesebastien ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT frisellthomas ageneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT jiangxia geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT asklingjohan geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT saevarsdottirsaedis geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT padyukovleonid geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT alfredssonlars geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT viattesebastien geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy
AT frisellthomas geneticriskscorecomposedofrheumatoidarthritisriskalleleshladrb1haplotypesandresponsetotnfitherapyresultsfromaswedishcohortstudy